



King's Research Portal

DOI:

[10.1042/NS20160020](https://doi.org/10.1042/NS20160020)

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Thornton, C. (2017). AMPK - keeping the (power)house in order. *Neuronal Signalling*.
<https://doi.org/10.1042/NS20160020>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Commentary

AMPK: keeping the (power)house in order?

Claire Thornton¹

¹Perinatal Brain Injury Group, Centre for the Developing Brain, Division of Imaging Sciences and Biomedical Engineering, King's College London, St. Thomas' Hospital, London SE1 7EH, U.K.

Correspondence: Claire Thornton (claire.thornton@kcl.ac.uk)



Metabolically energetic organs, such as the brain, require a reliable source of ATP, the majority of which is provided by oxidative phosphorylation in the mitochondrial matrix. Maintaining mitochondrial integrity is therefore of paramount importance in highly specialized cells such as neurons. Beyond acting as cellular 'power stations' and initiators of apoptosis, neuronal mitochondria are highly mobile, transported to pre- and post-synaptic sites for rapid, localized ATP production, serve to buffer physiological and pathological calcium and contribute to dendritic arborization. Given such roles, it is perhaps unsurprising that recent studies implicate AMP-activated protein kinase (AMPK), a cellular energy-sensitive metabolic regulator, in triggering mitochondrial fission, potentially balancing mitochondrial dynamics, biogenesis and mitophagy.

Although the brain constitutes approximately only 2% of our total body weight, it accounts for the usage of in excess of 20% of our oxygen intake and is one of the most metabolically active tissues in our bodies. Approximately 90% ATP production occurs through oxidative phosphorylation in mitochondria, therefore, for tissues with a high metabolic rate such as the brain, regulating mitochondrial health is key to sustaining cellular function [1].

Mitochondria are dynamic, double-membraned organelles that continually undergo fission, fusion and quality control (mitophagy) [2]. Long-term failure of either fission or fusion can lead to deleterious consequences and thus, a balance of these processes together with mitophagy is critical to maintaining cellular homeostasis. Over the last 20 years, there has been a flurry of interest in discerning the molecular mechanisms regulating this mitochondrial life cycle, with significant success. Inner and outer mitochondrial membrane fusion are governed by optic atrophy (OPA)1 and mitofusin1/2 respectively whereas fission is mediated by the cytosolic protein, dynamin-related protein (Drp)1 (Figure 1) [3]. Drp1 is recruited to the mitochondrial outer membrane by binding to one of a number of mitochondrially located adaptors such as mitochondrial fission factor (Mff) and mitochondrial fission protein (Fis)1, mitochondrial dynamics proteins of 49 and 51 kDa (MiD49/51) [2,4]. Mitophagy plays a key role in the life cycle of the mitochondrion. Not only does it ensure that damaged mitochondria are neutralized, but physiological mitophagy can also regulate the number of mitochondria and their turnover [5]. In response to the decorating of the outer membrane of a depolarized mitochondrion with ubiquitin, an isolation membrane is recruited to extend round and engulf the mitochondrion, subsequently fusing with a lysosome to acidify and recycle the contents (Figure 1). Fission is frequently observed as a prelude to mitophagy as well as in the initiation of apoptosis [6]. Fusion generates a mitochondrial reticulum, allowing mitochondrial contents to mix, preventing the accumulation of mitochondrial DNA mutations as well as promoting enhanced ATP synthesis through maintenance of respiratory complexes [7].

The metabolic sensor, AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase existing as a heterotrimer of catalytic ($\alpha 1/\alpha 2$) and regulatory subunits ($\beta 1/\beta 2$ and $\gamma 1/\gamma 2/\gamma 3$). The 12 possible heterotrimers exhibit tissue and potentially functional specificity [8], and all can be activated by binding of AMP/ADP to the AMPK γ subunit and phosphorylation by one of two upstream kinases, liver kinase B (LKB)1 or calcium/calmodulin-dependent protein kinase kinase (CaMKK) β . AMPK is activated in response to depletion of ATP or alterations in intracellular calcium concentrations, and acts to shut down ATP-consuming, anabolic pathways and promoting ATP-generating, catabolic pathways [9].

Received: 23 December 2016
Revised: 8 February 2017
Accepted: 9 February 2017

Accepted Manuscript online:
9 February 2017
Version of Record published:
24 March 2017




Figure 1. Mitochondrial dynamics

Fission, fusion and mitophagy exist in a delicate balance ensuring efficient ATP production (through fusion) and degradation of damaged mitochondria (through fission and mitophagy). Up-regulation of biogenesis restores fissioned daughter mitochondria to full ATP-producing efficiency; NRF1/2, nuclear respiratory factor 1/2; TFAM, mitochondrial transcription factor A. All other abbreviations are described in the text.

As a monitor of cellular and whole body energy status [10], it is probably unsurprising that a recent elegant study in *Science* from Reuben Shaw's laboratory places AMPK at the heart of the regulation of mitochondrial dynamics. Using CRISPR modification to delete AMPK α 1 and/or AMPK α 2 *in vitro*, they discovered that AMPK was critical to the fission response induced by mitochondrial poisons targeting the electron transport chain, such as rotenone; an absence of AMPK complexes resulted in an absence of fission [11]. Interestingly, direct pharmacological activation of AMPK was sufficient to promote fission, and equally effective regardless of whether AMPK α 1 or AMPK α 2-containing complexes were expressed. Toyama et al. further identified Mff as a substrate for AMPK phosphorylation, echoing a similar finding from the Sakamoto's laboratory where Mff was isolated in a proteomics screen for AMPK substrates in activated hepatocytes [12]. Mff is located on the outer mitochondrial membrane and acts to recruit Drp1, which subsequently oligomerizes and constricts the mitochondrion, leading to fission [13]. Toyama et al. [11] showed that AMPK-mediated phosphorylation of Mff at S155 and S172 is required for Drp1 recruitment, and *in vitro* studies of primary hepatocytes and primary cortical neurons imply that this mechanism could be ubiquitous. This study, therefore, identifies AMPK as the bridge between bioenergetic crisis and the induction of mitochondrial fission.

So is the fission-inducing action of AMPK conferring advantage or disadvantage to a neuron under siege? Reducing its ATP-producing capability during injury by dividing up mitochondria may not, at first glance, seem like a beneficial strategy, especially if it leads to the induction of apoptosis. However, fissioned mitochondria have a crucial role in neurons, as discrete mitochondria are required for axonal transport via microtubules to synaptic terminals, providing a local ATP source to fuel signal progression [14]. But as mentioned earlier, fission is also required as an initiating step in the progression of mitophagy, in which damaged mitochondria are cleared away, preventing elevated production of reactive oxygen species (ROS) as well as contributing to the restoration of efficient Ca²⁺-buffering capacity.

Coincidentally, among its large library of metabolic substrates, AMPK phosphorylates Unc-51-like kinase 1 (ULK1), a regulator of autophagy [15,16], which can itself regulate AMPK activity by phosphorylation [17]. Inhibiting AMPK-mediated ULK1 phosphorylation leads to accumulation of damaged mitochondria and prevention of mitophagy [15,18]. In addition, AMPK regulates peroxisome proliferator-activated receptor (PPAR) γ co-activator (PGC)-1 α , a master transcriptional activator of mitochondrial biogenesis, although whether this regulation is direct (by phosphorylation) or indirect (via SIRT1 deacetylation) is currently still debated [19,20]. Taken together, it is tempting to speculate that after metabolic insult, AMPK facilitates mitochondrial health in three distinct ways (Figure 2). Initially, in response to perturbations of the electron transport chain and subsequent ATP depletion, AMPK phosphorylates Mff, inducing fission. Concomitantly, activated AMPK can promote mitophagy of these small, damaged mitochondria through ULK1 phosphorylation as well as restore the daughter mitochondrion to full ATP production through PGC-1 α -mediated mitochondrial biogenesis. The suggested benefits imply a renewal of robust mitochondrial content within the cell, limiting damage and able to withstand cellular ATP demands. Such a mechanism may be in part responsible for the role of AMPK in pre-conditioning, a paradigm in which a sub-lethal stress




Figure 2. AMPK regulates mitochondrial health and may mediate pre-conditioning

Superimposed on this continuous mitochondrial life cycle is activated AMPK, which phosphorylates substrates at key points potentially tailoring a robust cellular response to pathological stimulus.

is evoked prior to the onset of lethal injury (Figure 2). This sub-lethal exposure renders cells more resistant to injury and pre-activation of AMPK has provided significant survival benefits in a wide range of ischaemic injuries [21–25].

However, while this wholesome scenario (in which AMPK promotes not only the sweeping away of ROS-producing mitochondria but also the energy efficiency of cell) is tempting, it is worth remembering that both fission and AMPK activation have independently been reported to mediate neurodegeneration. Fission occurs as an early event in a number of neurodegenerative diseases including Alzheimer's disease [26] and Huntington's disease [27] as well as occurring after brain trauma such as stroke or neonatal hypoxic-ischaemic injury [28,29], environments in which AMPK is known to be activated [30–32]. Indeed, inhibitors of post-injury fission, such as mDivi-1 and p110, have proved successful as neuroprotectants. As Drp1 interacts with a multitude of mitochondrial adaptors, further work is clearly required to determine differential contributions of these Drp1 binding partners, e.g. Fis1 in Huntington's disease [33]. It is also interesting to speculate that these findings might be a matter of timing. Inducing mitophagy too soon after injury could easily prove injurious if ATP production from damaged mitochondria (albeit limited) is more valuable to neuronal survival than the concomitant ROS accumulation. In such circumstances, delayed induction of mitophagy (through inhibition of fission) may well prove more and more advantageous treatment strategy. AMPK activity is also known to be up-regulated after brain injury in which there is ATP depletion. Not surprisingly then, the first evidence that AMPK activation may be deleterious was provided in a stroke model where it was found that pharmacological inhibition of AMPK or ablation of AMPK α 2 (but surprisingly not AMPK α 1) reduced infarct size [34,35]. Furthermore, and of specific interest here, recent studies have suggested that AMPK activation can induce fusion [36], that AMPK acts downstream of Drp1 [37] or even that AMPK directly phosphorylates Drp1 [38], inhibiting its capability for scission. These contradictory observations may very well be resolved once the contribution of the upstream kinases LKB1 and CaMKK β , AMPK subunit specificity, physiological compared with pathological AMPK stimuli (direct or indirect) and chronic compared with acute AMPK activation are deciphered. What is becoming clear though is that AMPK activation and mitochondrial dynamics are delicately intertwined, and modulating AMPK activity to maintain mitochondrial and, by extension, neuronal health remains an intriguing therapeutic possibility.

Funding

Work in the author's lab is generously funded by King's Health Partners Research and Development Challenge Fund.

Competing interests

The author declares that there are no competing interests associated with this manuscript.

Abbreviations

AMPK, AMP-activated protein kinase; CaMKK, calcium/calmodulin-dependent protein kinase kinase; Drp, dynamin-related protein; Fis, mitochondrial fission protein; LKB, liver kinase B; Mff, mitochondrial fission factor; MiD49/51, mitochondrial dynamics proteins of 49 and 51 kDa; OPA, optic atrophy; PGC-1 α , PPAR γ co-activator-1 α ; PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species; ULK1, Unc-51-like kinase 1.

References

- Rolfe, D.F. and Brown, G.C. (1997) Cellular energy utilization and molecular origin of standard metabolic rate in mammals. *Physiol. Rev.* **77**, 731–758 [PubMed](#)
- Youle, R.J. and van der Bliek, A.M. (2012) Mitochondrial fission, fusion, and stress. *Science* **337**, 1062–1065 [CrossRef PubMed](#)
- MacVicar, T. and Langer, T. (2016) OPA1 processing in cell death and disease – the long and short of it. *J. Cell Sci.* **129**, 2297–2306 [CrossRef PubMed](#)
- van der Bliek, A.M., Shen, Q. and Kawajiri, S. (2013) Mechanisms of mitochondrial fission and fusion. *Cold Spring Harb. Perspect. Biol.* **5**, a011072 [CrossRef PubMed](#)
- Youle, R.J. and Narendra, D.P. (2011) Mechanisms of mitophagy. *Nat. Rev. Mol. Cell Biol.* **12**, 9–14 [CrossRef PubMed](#)
- Balog, J., Mehta, S.L. and Vemuganti, R. (2016) Mitochondrial fission and fusion in secondary brain damage after CNS insults. *J. Cereb. Blood Flow Metab.* **36**, 2022–2033 [CrossRef PubMed](#)
- Liesa, M. and Shirihai, O.S. (2013) Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. *Cell Metab.* **17**, 491–506 [CrossRef PubMed](#)
- Ross, F.A., MacKintosh, C. and Hardie, D.G. (2016) AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours. *FEBS J.* **283**, 2987–3001 [CrossRef PubMed](#)
- Carling, D., Thornton, C., Woods, A. and Sanders, M.J. (2012) AMP-activated protein kinase: new regulation, new roles? *Biochem. J.* **445**, 11–27 [CrossRef PubMed](#)
- Carling, D., Mayer, F.V., Sanders, M.J. and Gamblin, S.J. (2011) AMP-activated protein kinase: nature's energy sensor. *Nat. Chem. Biol.* **7**, 512–518 [CrossRef PubMed](#)
- Toyama, E.Q., Herzig, S., Courchet, J., Lewis, Jr, T.L., Loson, O.C., Hellberg, K. et al. (2016) Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. *Science* **351**, 275–281 [CrossRef PubMed](#)
- Ducommun, S., Deak, M., Sumpton, D., Ford, R.J., Nunez Galindo, A., Kussmann, M. et al. (2015) Motif affinity and mass spectrometry proteomic approach for the discovery of cellular AMPK targets: identification of mitochondrial fission factor as a new AMPK substrate. *Cell. Signal.* **27**, 978–988 [CrossRef PubMed](#)
- Ingerman, E., Perkins, E.M., Marino, M., Mears, J.A., McCaffery, J.M., Hinshaw, J.E. et al. (2005) Dnm1 forms spirals that are structurally tailored to fit mitochondria. *J. Cell. Biol.* **170**, 1021–1027 [CrossRef PubMed](#)
- Saxton, W.M. and Hollenbeck, P.J. (2012) The axonal transport of mitochondria. *J. Cell. Sci.* **125**, 2095–2104 [CrossRef PubMed](#)
- Egan, D.F., Shackelford, D.B., Mihaylova, M.M., Gelino, S., Kohnz, R.A., Mair, W. et al. (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science* **331**, 456–461 [CrossRef PubMed](#)
- Kim, J., Kundu, M., Viollet, B. and Guan, K.L. (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat. Cell Biol.* **13**, 132–141 [CrossRef PubMed](#)
- Löffler, A.S., Alers, S., Dieterle, A.M., Keppeler, H., Franz-Wachtel, M., Kundu, M. et al. (2011) Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop. *Autophagy* **7**, 696–706 [CrossRef PubMed](#)
- Tian, W., Li, W., Chen, Y., Yan, Z., Huang, X., Zhuang, H. et al. (2015) Phosphorylation of ULK1 by AMPK regulates translocation of ULK1 to mitochondria and mitophagy. *FEBS Lett.* **589**, 1847–1854 [CrossRef PubMed](#)
- Canto, C., Jiang, L.Q., Deshmukh, A.S., Matak, C., Coste, A., Lagouge, M. et al. (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. *Cell. Metab.* **11**, 213–219 [CrossRef PubMed](#)
- Jager, S., Handschin, C., St-Pierre, J. and Spiegelman, B.M. (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1 α . *Proc. Natl. Acad. Sci. U.S.A.* **104**, 12017–12022 [CrossRef PubMed](#)
- Anilkumar, U., Weisova, P., Dussmann, H., Concannon, C.G., König, H.G. and Prehn, J.H. (2013) AMP-activated protein kinase (AMPK)-induced preconditioning in primary cortical neurons involves activation of MCL-1. *J. Neurochem.* **124**, 721–734 [CrossRef PubMed](#)
- Coughlan, K.S., Mitchem, M.R., Hogg, M.C. and Prehn, J.H. (2015) "Preconditioning" with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. *Neurobiol. Aging* **36**, 1140–1150 [CrossRef PubMed](#)
- Jiang, T., Yu, J.T., Zhu, X.C., Zhang, Q.Q., Tan, M.S., Cao, L. et al. (2014) Ischemic preconditioning provides neuroprotection by induction of AMP-activated protein kinase-dependent autophagy in a rat model of ischemic stroke. *Mol. Neurobiol.* **51**, 220–229 [CrossRef PubMed](#)
- Jiang, T., Yu, J.T., Zhu, X.C., Wang, H.F., Tan, M.S., Cao, L. et al. (2014) Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. *Br. J. Pharmacol.* **171**, 3146–3157 [CrossRef PubMed](#)
- Weisova, P., Anilkumar, U., Ryan, C., Concannon, C.G., Prehn, J.H. and Ward, M.W. (2012) 'Mild mitochondrial uncoupling' induced protection against neuronal excitotoxicity requires AMPK activity. *Biochim. Biophys. Acta* **1817**, 744–753 [CrossRef PubMed](#)
- Cho, D.H., Nakamura, T., Fang, J., Cieplak, P., Godzik, A., Gu, Z. et al. (2009) S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. *Science* **324**, 102–105 [CrossRef PubMed](#)
- Song, W., Chen, J., Petrilli, A., Liot, G., Klinglmayr, E., Zhou, Y. et al. (2011) Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. *Nat. Med.* **17**, 377–382 [CrossRef PubMed](#)
- Baburamani, A.A., Hurling, C., Stolp, H., Sobotka, K., Gressens, P., Hagberg, H. et al. (2015) Mitochondrial optic atrophy (OPA) 1 processing is altered in response to neonatal hypoxic-ischemic brain injury. *Int. J. Mol. Sci.* **16**, 22509–22526 [CrossRef PubMed](#)
- Sanderson, T.H., Raghunayakula, S. and Kumar, R. (2015) Neuronal hypoxia disrupts mitochondrial fusion. *Neuroscience* **301**, 71–78 [CrossRef PubMed](#)
- Manwani, B. and McCullough, L.D. (2013) Function of the master energy regulator adenosine monophosphate-activated protein kinase in stroke. *J. Neurosci. Res.* **91**, 1018–1029 [CrossRef PubMed](#)
- Perera, N.D. and Turner, B.J. (2016) AMPK signalling and defective energy metabolism in amyotrophic lateral sclerosis. *Neurochem. Res.* **41**, 544–553 [CrossRef PubMed](#)

- 32 Hang, L., Thundiyil, J. and Lim, K.L. (2015) Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection. *Ann. N.Y. Acad. Sci.* **1350**, 37–47 [CrossRef](#) [PubMed](#)
- 33 Shirendeb, U., Reddy, A.P., Manczak, M., Calkins, M.J., Mao, P., Tagle, D.A. et al. (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. *Hum. Mol. Genet.* **20**, 1438–1455 [CrossRef](#) [PubMed](#)
- 34 Li, J., Zeng, Z., Violet, B., Ronnett, G.V. and McCullough, L.D. (2007) Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke. *Stroke* **38**, 2992–2999 [CrossRef](#) [PubMed](#)
- 35 McCullough, L.D., Zeng, Z., Li, H., Landree, L.E., McFadden, J. and Ronnett, G.V. (2005) Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. *J. Biol. Chem.* **280**, 20493–20502 [CrossRef](#) [PubMed](#)
- 36 Kang, S.W., Haydar, G., Taniane, C., Farrell, G., Arias, I.M., Lippincott-Schwartz, J. et al. (2016) AMPK activation prevents and reverses drug-induced mitochondrial and hepatocyte injury by promoting mitochondrial fusion and function. *PLoS One* **11**, e0165638 [CrossRef](#) [PubMed](#)
- 37 Xie, Q., Wu, Q., Horbinski, C.M., Flavahan, W.A., Yang, K., Zhou, W. et al. (2015) Mitochondrial control by DRP1 in brain tumor initiating cells. *Nat. Neurosci.* **18**, 501–510 [CrossRef](#) [PubMed](#)
- 38 Li, J., Wang, Y., Wang, Y., Wen, X., Ma, X.N., Chen, W. et al. (2015) Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction. *J. Mol. Cell. Cardiol.* **86**, 62–74 [CrossRef](#) [PubMed](#)